These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 7872321)

  • 1. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin.
    Wingard RL; Parker RA; Ismail N; Hakim RM
    Am J Kidney Dis; 1995 Mar; 25(3):433-9. PubMed ID: 7872321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective open-label study evaluating the efficacy and adverse reactions of the use of Niferex-150 in ESRD patients receiving EPOGEN.
    Johnson CA; Rosowski E; Zimmerman SW
    Adv Perit Dial; 1992; 8():444-7. PubMed ID: 1361844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin.
    Kotaki M; Uday K; Henriquez M; Blum S; Dave M
    Clin Nephrol; 1997 Jul; 48(1):63-4. PubMed ID: 9247787
    [No Abstract]   [Full Text] [Related]  

  • 4. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin.
    Markowitz GS; Kahn GA; Feingold RE; Coco M; Lynn RI
    Clin Nephrol; 1997 Jul; 48(1):34-40. PubMed ID: 9247776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis.
    Silverberg DS; Iaina A; Peer G; Kaplan E; Levi BA; Frank N; Steinbruch S; Blum M
    Am J Kidney Dis; 1996 Feb; 27(2):234-8. PubMed ID: 8659499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anemia management of adult hemodialysis patients in the US results: from the 1997 ESRD Core Indicators Project.
    Frankenfield D; Johnson CA; Wish JB; Rocco MV; Madore F; Owen WF
    Kidney Int; 2000 Feb; 57(2):578-89. PubMed ID: 10652035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietin therapy in pre-dialysis patients with chronic renal failure: lack of need for parenteral iron.
    Trivedi HS; Brooks BJ
    Am J Nephrol; 2003; 23(2):78-85. PubMed ID: 12481145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron management during recombinant human erythropoietin therapy.
    Van Wyck DB
    Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):9-13. PubMed ID: 2757026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Assessment of iron requirements during treatment of anemia with recombinant human erythropoietin in patients with chronic renal insufficiency under hemodialysis].
    Oliveira C; Boquinhas H; Gaspar A; Adragão T; Boquinhas JM; Júnior EC; Simões J
    Acta Med Port; 1992 Jul; 5(7):351-7. PubMed ID: 1442178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical evaluation of heme iron polypeptide: sustaining a response to rHuEPO in hemodialysis patients.
    Nissenson AR; Berns JS; Sakiewicz P; Ghaddar S; Moore GM; Schleicher RB; Seligman PA
    Am J Kidney Dis; 2003 Aug; 42(2):325-30. PubMed ID: 12900815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous iron dextran and erythropoietin use in pediatric hemodialysis patients.
    Greenbaum LA; Pan CG; Caley C; Nelson T; Sheth KJ
    Pediatr Nephrol; 2000 Sep; 14(10-11):908-11. PubMed ID: 10975297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation.
    Fishbane S; Frei GL; Maesaka J
    Am J Kidney Dis; 1995 Jul; 26(1):41-6. PubMed ID: 7611266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran--a comparison of two products.
    McCarthy JT; Regnier CE; Loebertmann CL; Bergstralh EJ
    Am J Nephrol; 2000; 20(6):455-62. PubMed ID: 11146312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients.
    Fishbane S; Lynn RI
    Clin Nephrol; 1995 Oct; 44(4):238-40. PubMed ID: 8575123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The utility of zinc protoporphyrin for predicting the need for intravenous iron therapy in hemodialysis patients.
    Fishbane S; Lynn RI
    Am J Kidney Dis; 1995 Mar; 25(3):426-32. PubMed ID: 7872320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure.
    Ahluwalia N; Skikne BS; Savin V; Chonko A
    Am J Kidney Dis; 1997 Oct; 30(4):532-41. PubMed ID: 9328369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO.
    Mittman N; Sreedhara R; Mushnick R; Chattopadhyay J; Zelmanovic D; Vaseghi M; Avram MM
    Am J Kidney Dis; 1997 Dec; 30(6):912-22. PubMed ID: 9398141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of erythropoietin in human immunodeficiency virus-infected end-stage renal disease patients treated by maintenance hemodialysis.
    Shrivastava D; Rao TK; Sinert R; Khurana E; Lundin AP; Friedman EA
    Am J Kidney Dis; 1995 Jun; 25(6):904-9. PubMed ID: 7771487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
    Li H; Wang SX
    Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind, placebo-controlled trial.
    Kleinman KS; Schweitzer SU; Perdue ST; Bleifer KH; Abels RI
    Am J Kidney Dis; 1989 Dec; 14(6):486-95. PubMed ID: 2688405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.